Implementation and Outcomes of a Molecular Tumor Board at Herbert-Herman Cancer Center, Sparrow Hospital

Authors

  • Harsha Trivedi Herbert-Herman Cancer Center, Sparrow Hospital
  • Devansh Acharya Herbert-Herman Cancer Center, Sparrow Hospital
  • Ushasree Chamarthy Herbert-Herman Cancer Center, Sparrow Hospital
  • Joseph Meunier Herbert-Herman Cancer Center, Sparrow Hospital
  • Hussein Ali-Ahmad Herbert-Herman Cancer Center, Sparrow Hospital
  • Muhammad Hamdan Herbert-Herman Cancer Center, Sparrow Hospital
  • James Herman Herbert-Herman Cancer Center, Sparrow Hospital
  • Gordan Srkalovic Herbert-Herman Cancer Center, Sparrow Hospital

DOI:

https://doi.org/10.5644/ama2006-124.247

Keywords:

Molecular Tumor Board, Precision Medicine, Targeted Therapy, Genomic Profiling

Abstract

Objective. This paper describes our experience and outcomes from 54 cases presented to the (Molecular tumor board) MTB.

Methods. 54 Cases presented between July 2017 and April 2018 were included in this analysis. These patients had different types of cancers that had either failed standard therapy or were expected to fail and physicians were looking for future options for anticipated progression. Patients who had obvious mutations and were candidates for Targeted Agent and Profiling Utilization Registry or Molecular Analysis for Treatment Choice clinical trials were not included. Oncologists presented the cases virtually and Foundation Medicine scientific and clinical team discussed the molecular pathways to find targeted options or trials. Tumor board attendees included oncologists, nurses, pharmacists, mid-level providers, residents and staff of the Cancer Center.

Results. Amongst the 54 cases presented 81% had one or more potentially actionable alteration. 12 (22%) patients received genomically matched therapy as per MTB recommendations. Additional 13 (24%) patients have options available when they progress. Out of 12 patients who got treatment six are alive at the time of this analysis. Genomically matched therapy or Clinical Trials option were offered to the 46% of patients based on the MTB discussion.

Conclusion. More widespread use of molecular diagnostics, better physician education and multidisciplinary collaboration between the staff involved in diagnosis and treatment, as well as third party payers are necessary for consensus on treatment and care of oncology patients.

Downloads

Download data is not yet available.

Downloads

Published

2019-06-26

How to Cite

Trivedi, H., Acharya, D., Chamarthy, U., Meunier, J., Ali-Ahmad, H., Hamdan, M., Herman, J., & Srkalovic, G. (2019). Implementation and Outcomes of a Molecular Tumor Board at Herbert-Herman Cancer Center, Sparrow Hospital. Acta Medica Academica, 48(1), 105–115. https://doi.org/10.5644/ama2006-124.247

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.